{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:49:59Z","timestamp":1790628599284,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T00:00:00Z","timestamp":1710028800000},"content-version":"vor","delay-in-days":69,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016198","name":"Idorsia Pharmaceuticals Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Applied"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.nsa.2024.104056","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T05:29:45Z","timestamp":1710566985000},"page":"104056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Anxiolytic-like effects of the dual orexin receptor antagonist daridorexant in rats"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9923-6555","authenticated-orcid":false,"given":"Michel Alexander","family":"Steiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekka","family":"Locher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Lecourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Jenck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nsa.2024.104056_bib1","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.neuroscience.2006.07.018","article-title":"Excitatory action of hypocretin\/orexin on neurons of the central medial amygdala","volume":"142","author":"Bisetti","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.nsa.2024.104056_bib2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3389\/fphar.2017.00357","article-title":"Evaluation of JNJ-54717793 a novel brain penetrant selective orexin 1 receptor antagonist in two rat models of panic attack provocation","volume":"8","author":"Bonaventure","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.nsa.2024.104056_bib3","article-title":"Proline sulfonamide derivatives as orexin receptor antagonists","author":"Boss","year":"2012","journal-title":"PCT Int. Pat. Appl."},{"key":"10.1016\/j.nsa.2024.104056_bib4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nm1544","article-title":"Promotion of sleep by targeting the orexin system in rats, dogs and humans","volume":"13","author":"Brisbare-Roch","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.nsa.2024.104056_bib5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fnins.2013.00257","article-title":"Orexin, orexin receptor antagonists and central cardiovascular control","volume":"7","author":"Carrive","year":"2013","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.nsa.2024.104056_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsy048","article-title":"Assessment of sympathetic neural activity in chronic insomnia: evidence for elevated cardiovascular risk","volume":"41","author":"Carter","year":"2018","journal-title":"Sleep"},{"key":"10.1016\/j.nsa.2024.104056_bib7","article-title":"Orexins (hypocretins) contribute to fear and avoidance in rats exposed to a single episode of footshocks","author":"Chen","year":"2013","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.nsa.2024.104056_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0167-0115(00)00202-0","article-title":"Orexins: a role in medullary sympathetic outflow","volume":"96","author":"Dun","year":"2000","journal-title":"Regul. Pept."},{"key":"10.1016\/j.nsa.2024.104056_bib9","author":"Eisai"},{"key":"10.1016\/j.nsa.2024.104056_bib10","series-title":"Marketing Authorization of Quiviviq","author":"EMA","year":"2022"},{"key":"10.1016\/j.nsa.2024.104056_bib11","first-page":"CD010753","article-title":"Antidepressants for insomnia in adults","volume":"5","author":"Everitt","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.nsa.2024.104056_bib12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12017-007-8001-2","article-title":"The orexin 1 receptor (HCRTR1) gene as a susceptibility gene contributing to polydipsia-hyponatremia in schizophrenia","volume":"9","author":"Fukunaka","year":"2007","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.nsa.2024.104056_bib13","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/j.1460-9568.2009.06952.x","article-title":"Hypocretin\/orexin contributes to the expression of some but not all forms of stress and arousal","volume":"30","author":"Furlong","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.nsa.2024.104056_bib14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/adb.12507","article-title":"Suvorexant, an orexin\/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine","volume":"23","author":"Gentile","year":"2018","journal-title":"Addiction Biol."},{"key":"10.1016\/j.nsa.2024.104056_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11395","article-title":"Awake dynamics and brain-wide direct inputs of hypothalamic MCH and orexin networks","volume":"7","author":"Gonzalez","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.nsa.2024.104056_bib16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41398-022-02090-x","article-title":"Acute orexin antagonism selectively modulates anticipatory anxiety in humans: implications for addiction and anxiety","volume":"12","author":"Gorka","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.nsa.2024.104056_bib17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00213-007-1019-1","article-title":"Models and mechanisms of anxiety: evidence from startle studies","volume":"199","author":"Grillon","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nsa.2024.104056_bib18","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/pds.5004","article-title":"Association of eszopiclone, zaleplon, or zolpidem with complex sleep behaviors resulting in serious injuries, including death","volume":"29","author":"Harbourt","year":"2020","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.nsa.2024.104056_bib19","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0306-4522(01)00033-1","article-title":"Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord","volume":"103","author":"Hervieu","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.nsa.2024.104056_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1152\/jn.00064.2018","article-title":"Relative burst amplitude of muscle sympathetic nerve activity is an indicator of altered sympathetic outflow in chronic anxiety","volume":"120","author":"Holwerda","year":"2018","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.nsa.2024.104056_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0165-1781(95)02673-K","article-title":"Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity","volume":"57","author":"Jenck","year":"1995","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.nsa.2024.104056_bib22","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/da.22403","article-title":"Orexin 1 and 2 receptor involvement in Co2 -induced panic-associated behavior and autonomic responses","volume":"32","author":"Johnson","year":"2015","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.nsa.2024.104056_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2021.627633","article-title":"The paraventricular nucleus of the thalamus as an integrating and relay node in the brain anxiety network","volume":"15","author":"Kirouac","year":"2021","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.nsa.2024.104056_bib24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.brainres.2005.08.035","article-title":"Orexin (hypocretin) innervation of the paraventricular nucleus of the thalamus","volume":"1059","author":"Kirouac","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.nsa.2024.104056_bib25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/wps.20674","article-title":"The assessment and management of insomnia: an update","volume":"18","author":"Krystal","year":"2019","journal-title":"World Psychiatr."},{"key":"10.1016\/j.nsa.2024.104056_bib26","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1113\/jphysiol.2013.256271","article-title":"Antagonism of orexin receptors significantly lowers blood pressure in spontaneously hypertensive rats","volume":"591","author":"Li","year":"2013","journal-title":"J. Physiol."},{"key":"10.1016\/j.nsa.2024.104056_bib27","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.physbeh.2012.05.019","article-title":"Orexin-A induces anxiety-like behavior through interactions with glutamatergic receptors in the bed nucleus of the stria terminalis of rats","volume":"107","author":"Lungwitz","year":"2012","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.nsa.2024.104056_bib28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0031-9384(92)90290-I","article-title":"Psychological stress and body temperature changes in humans","volume":"52","author":"Marazziti","year":"1992","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.nsa.2024.104056_bib29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.biopsych.2005.04.015","article-title":"Association of an orexin 1 receptor 408Val variant with polydipsia-hyponatremia in schizophrenic subjects","volume":"58","author":"Meerabux","year":"2005","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.nsa.2024.104056_bib30","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00213-011-2570-3","article-title":"Schedule-induced polydipsia as a model of compulsive behavior: neuropharmacological and neuroendocrine bases","volume":"219","author":"Moreno","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nsa.2024.104056_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12051975","article-title":"What should Be the focus of treatment when insomnia disorder is comorbid with depression or anxiety disorder?","volume":"12","author":"Morin","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.nsa.2024.104056_bib32","article-title":"Insomnia disorder","volume":"1","author":"Morin","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.nsa.2024.104056_bib33","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/17425255.2020.1817380","article-title":"Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders","volume":"16","author":"Muehlan","year":"2020","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.nsa.2024.104056_bib34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0006-8993(99)01336-0","article-title":"Distribution of orexin neurons in the adult rat brain","volume":"827","author":"Nambu","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.nsa.2024.104056_bib35","unstructured":"NCT03642028; study identifier at https:\/\/clinicaltrials.gov; Suvorexant: a dual orexin receptor antagonist for treating sleep disturbance in posttraumatic stress."},{"key":"10.1016\/j.nsa.2024.104056_bib36","unstructured":"NCT05948540; study identifier at https:\/\/clinicaltrials.gov; Department of defense PTSD adaptive platform trial - Intervention. C - Daridorexant."},{"key":"10.1016\/j.nsa.2024.104056_bib37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0006-8993(99)02334-3","article-title":"Strain differences to the effects of aversive frequency ultrasound on behaviour and brain topography of c-fos expression in the rat","volume":"854","author":"Neophytou","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.nsa.2024.104056_bib38","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00213-007-0838-4","article-title":"Defensive-like behaviors induced by ultrasound: further pharmacological characterization in Lister-hooded rats","volume":"194","author":"Nicolas","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nsa.2024.104056_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0022-3956(02)00052-3","article-title":"Place of chronic insomnia in the course of depressive and anxiety disorders","volume":"37","author":"Ohayon","year":"2003","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.nsa.2024.104056_bib40","first-page":"1","article-title":"Factors associated with prescriptions for an orexin receptor antagonist among Japanese patients with insomnia: analysis of a nationwide Japanese claims database","author":"Okuda","year":"2023","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.nsa.2024.104056_bib41","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/npp.2012.48","article-title":"Role of orexin-1 receptor mechanisms on compulsive food consumption in a model of binge eating in female rats","volume":"37","author":"Piccoli","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.nsa.2024.104056_bib42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/2042098615595359","article-title":"Suvorexant in insomnia: efficacy, safety and place in therapy","volume":"6","author":"Rhyne","year":"2015","journal-title":"Ther. Adv. Drug Saf."},{"key":"10.1016\/j.nsa.2024.104056_bib43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.smrv.2009.04.002","article-title":"The hyperarousal model of insomnia: a review of the concept and its evidence","volume":"14","author":"Riemann","year":"2010","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.nsa.2024.104056_bib44","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s00213-021-05954-0","article-title":"Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia","volume":"238","author":"Roch","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nsa.2024.104056_bib45","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.biopsych.2006.05.039","article-title":"Sleep problems, comorbid mental disorders, and role functioning in the national comorbidity survey replication","volume":"60","author":"Roth","year":"2006","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.nsa.2024.104056_bib46","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41398-020-00937-9","article-title":"Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans","volume":"10","author":"Salvadore","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.nsa.2024.104056_bib47","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12877-022-02757-6","article-title":"Efficacy and safety of Z-substances in the management of insomnia in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing","volume":"22","author":"Scharner","year":"2022","journal-title":"BMC Geriatr."},{"key":"10.1016\/j.nsa.2024.104056_bib48","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0014-2999(01)01562-X","article-title":"Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608)","volume":"435","author":"Spooren","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.nsa.2024.104056_bib49","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/cmdc.201300003","article-title":"Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist","volume":"8","author":"Steiner","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.nsa.2024.104056_bib50","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00213-012-2736-7","article-title":"The brain orexin system and almorexant in fear-conditioned startle reactions in the rat","volume":"223","author":"Steiner","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nsa.2024.104056_bib51","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejphar.2008.02.097","article-title":"Translational aspects of pharmacological research into anxiety disorders: the stress-induced hyperthermia (SIH) paradigm","volume":"585","author":"Vinkers","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.nsa.2024.104056_bib52","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00213-014-3769-x","article-title":"Orexin neuropeptides contribute to the development and persistence of generalized avoidance behavior in the rat","volume":"232","author":"Viviani","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nsa.2024.104056_bib53","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.neuroscience.2017.01.003","article-title":"Differential behavioral sensitivity to carbon dioxide (CO(2)) inhalation in rats","volume":"346","author":"Winter","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.nsa.2024.104056_bib54","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1001\/jama.2020.19224","article-title":"Trends in dispensing of zolpidem and low-dose trazodone among commercially insured adults in the United States, 2011-2018","volume":"324","author":"Wong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.nsa.2024.104056_bib55","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/cne.20859","article-title":"Afferents to the orexin neurons of the rat brain","volume":"494","author":"Yoshida","year":"2006","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.nsa.2024.104056_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2023.101746","article-title":"Efficacy and tolerability of pharmacological treatments for insomnia in adults: a systematic review and network meta-analysis","volume":"68","author":"Yue","year":"2023","journal-title":"Sleep Med. Rev."}],"container-title":["Neuroscience Applied"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772408524001212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772408524001212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T07:15:28Z","timestamp":1731482128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772408524001212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":56,"alternative-id":["S2772408524001212"],"URL":"https:\/\/doi.org\/10.1016\/j.nsa.2024.104056","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3011063\/v1","asserted-by":"object"}]},"ISSN":["2772-4085"],"issn-type":[{"value":"2772-4085","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anxiolytic-like effects of the dual orexin receptor antagonist daridorexant in rats","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Applied","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nsa.2024.104056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Idorsia Pharmaceuticals Ltd. Published by Elsevier B.V. on behalf of European College of Neuropsychopharmacology.","name":"copyright","label":"Copyright"}],"article-number":"104056"}}